One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 225,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) on Tuesday, as the share price of this fund traded down over 2% in the day’s session. The fund’s share price has greatly improved over the past year.

ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 228,234 shares of Takeda Pharma. At Tuesday’s closing price, this would have valued this sale at roughly $3.9 million. This is only a small fraction of the total holdings. This fund is up 88% over the past 52 weeks.

Here is a quick look at all the other sales that took place across all ARK ETFs:

Fund	Ticker	Company	Shares
ARKF	TCSLI	TCS GROUP HOLDING PLC	50,650
ARKG	PSTI	PLURISTEM THERAPEUTICS INC	1,131
ARKG	NVS	NOVARTIS AG	139,576
ARKG	SRPT	SAREPTA THERAPEUTICS INC	48,004
ARKG	TAK	TAKEDA PHARMACEUTICAL CO LTD	228,234
ARKK	ICE	INTERCONTINENTAL EXCHANGE INC	196,304
ARKQ	TER	TERADYNE INC	23,160
ARKQ	RAVN	RAVEN INDUSTRIES INC	32,733
ARKQ	GLEO	GALILEO ACQUISITION CORP	5,888
ARKW	NET	CLOUDFLARE INC	72,257
ARKX	AIRFP	AIRBUS SE	16,050

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.